Genital Herpes - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Genital Herpes – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Genital Herpes: Overview
Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. The first signs of genital herpes usually show up two to 12 days after having sexual contact with someone who has herpes. Symptoms can last from two to four weeks. There are other early symptoms of genital herpes: Feeling of pressure in the abdomen, Flu-like symptoms, including fever, Itching or burning feeling in the genital or anal area, Pain in the legs, buttocks, or genital area, Swollen glands, and Unusual vaginal discharge. The laboratory diagnosis of acute genital HSV infection or asymptomatic virus shedding is made via direct viral detection. The method of choice is demonstration of viral genomes in skin or mucous membrane swabs using the polymerase chain reaction (PCR). Standard first-line drugs include acyclovir, valacyclovir and famciclovir. The specific antiviral action of these acyclic nucleoside analogues is based on their phosphorylation to monophosphate form by thymidine kinase (TK), the key enzyme of HSV-1 and HSV-2, with subsequent phosphorylation via di- to triphosphate form by cellular enzymes.
'Genital Herpes - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital Herpes pipeline landscape is provided which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces, in depth Genital Herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Genital Herpes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Genital Herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Genital Herpes Emerging Drugs
Further product details are provided in the report……..
Genital Herpes: Therapeutic Assessment
This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:
Genital Herpes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Genital Herpes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Herpes drugs.
Genital Herpes Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Genital Herpes – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Genital Herpes: Overview
Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. The first signs of genital herpes usually show up two to 12 days after having sexual contact with someone who has herpes. Symptoms can last from two to four weeks. There are other early symptoms of genital herpes: Feeling of pressure in the abdomen, Flu-like symptoms, including fever, Itching or burning feeling in the genital or anal area, Pain in the legs, buttocks, or genital area, Swollen glands, and Unusual vaginal discharge. The laboratory diagnosis of acute genital HSV infection or asymptomatic virus shedding is made via direct viral detection. The method of choice is demonstration of viral genomes in skin or mucous membrane swabs using the polymerase chain reaction (PCR). Standard first-line drugs include acyclovir, valacyclovir and famciclovir. The specific antiviral action of these acyclic nucleoside analogues is based on their phosphorylation to monophosphate form by thymidine kinase (TK), the key enzyme of HSV-1 and HSV-2, with subsequent phosphorylation via di- to triphosphate form by cellular enzymes.
'Genital Herpes - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital Herpes pipeline landscape is provided which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces, in depth Genital Herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Genital Herpes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve Genital Herpes.
This segment of the Genital Herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Genital Herpes Emerging Drugs
- Pritelivir: AiCuris
- UB-621: United Biopharma
- HDIT 101: Heidelberg ImmunoTherapeutics
Further product details are provided in the report……..
Genital Herpes: Therapeutic Assessment
This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Genital Herpes
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Genital Herpes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Genital Herpes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Herpes drugs.
Genital Herpes Report Insights
- Genital Herpes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Genital Herpes drugs?
- How many Genital Herpes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital Herpes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Genital Herpes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Genital Herpes and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Genital Herpes: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Pritelivir: AiCuris
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
UB-621: United Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
HSV 2 Vaccines: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Genital Herpes Key Companies
Genital Herpes Key Products
Genital Herpes- Unmet Needs
Genital Herpes- Market Drivers and Barriers
Genital Herpes- Future Perspectives and Conclusion
Genital Herpes Analyst Views
Genital Herpes Key Companies
Appendix
Executive Summary
Genital Herpes: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Pritelivir: AiCuris
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
UB-621: United Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I/II)
Comparative Analysis
HSV 2 Vaccines: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Genital Herpes Key Companies
Genital Herpes Key Products
Genital Herpes- Unmet Needs
Genital Herpes- Market Drivers and Barriers
Genital Herpes- Future Perspectives and Conclusion
Genital Herpes Analyst Views
Genital Herpes Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Genital Herpes
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Genital Herpes
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Genital Herpes
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Genital Herpes
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
